Stat4Onc Annual Symposium

项目摘要/摘要 癌症是美国第二大死因。统计设计和数据分析方法 在最近开发更有效的癌症治疗方法方面起到了重要作用。在成功的同时 就像i-SPY2试验强调的那样，大多数肿瘤学试验并没有充分利用强大的 统计创新和肿瘤学家之间仍然缺乏有效的沟通 和统计学家。为了解决这些问题，我们提出了Stat4Onc研讨会，它提供了 肿瘤学家和统计学家讨论和交流新闻思想的独特平台 癌症临床试验、疾病诊断、病人护理和药物决策中的问题 发展。这次研讨会将进一步推动统计方法和数据的创新 致力于肿瘤学研究的分析，并将这些创新转化为研究实践。它 也为肿瘤学和统计学的实习生提供了一个学习跨学科的场所 合作。研讨会将在四所参赛大学之间轮流举行，每五年举行一次- 年度资金期。研讨会为期三天，与第一天的短期课程相关 以年度为主题，然后是为期两天的单轨科学计划。研讨会的主题是 包括肿瘤学、统计学、监管和数据科学方面的科学专门知识， 他们的专业协会来自学术界(教职员工和学生)、生物制药和 生物技术行业、政府机构和非营利组织，以及性别和种族， 特别是将代表人数不足的少数群体包括在内。研讨会的规模将是 约200人参加，允许进行充分和集中的讨论。研讨会将是 单次跟踪，允许参与者参与所有会话。主旨演讲和所有会议 将有来自学术、政府和行业的演讲者，并具有肿瘤学和 统计数据。肿瘤学和统计学两个学科的学员将被支持参加 研讨会，并提供在海报和交流会上展示的机会。研讨会座谈 将发表在JCO精密肿瘤学和新英格兰数据统计杂志上 科学。

Project Summary/Abstract Cancer is the 2nd leading cause of death in US. Statistical designs and data analytics approaches are instrumental in recent development of more effective treatments for cancer. While successes like the I-SPY2 trial highlight the advancement, most oncology trials do not fully utilize powerful statistical innovations and there remains a lack of effective communications between oncologists and statisticians. To address these issues, we propose the Stat4Onc symposium which provides a unique platform for oncologists and statisticians to discuss and exchange ideas for pressing issues in cancer clinical trials, disease diagnosis, patient care, and decision making for drug development. This symposium will further drive innovations in statistical methodology and data analytics dedicated for oncology research and translate these innovations to research practice. It also provides a venue for trainees in oncology and statistics to learn inter-disciplinary collaborations. The symposium will be rotated among the four participating universities in a five- year funding period. The symposium is a three-day event, with first day of short courses relevant to the theme of the year, and then a two-day single-track scientific program. The symposium is inclusive, with respect to scientific expertise in oncology, statistics, regulatory and data sciences, to their professional associations from academia (faculty, staff, and students), biopharma and biotech industry, government agencies, and non-profit organizations, and to gender and ethnicity, in particular for the inclusion of underrepresented minority groups. The symposium size will be around 200 participants, allowing adequate and focused discussions. The symposium will be single tracked to allow participants to be in all the sessions. Keynote talks and all the sessions will have speakers from academic, government, and industry and with expertise in oncology and statistics. Trainees in both oncology and statistics disciplines will be supported for attending the symposium and offers opportunities to present in poster and mixer sessions. Symposium talks will be published in JCO Precision Oncology and New England Journal of Statistics in Data Science.